Breaking News

Baker Hughes Awarded Long-Term Service Agreement by bp for Tangguh LNG Operations, Supporting Indonesia's Energy Future

Baker Hughes Awarded Long-Term Service Agreement by bp for Tangguh LNG Operations, Supporting Indonesia's Energy Future

Baker Hughes secured a 90-month service agreement with bp for the Tangguh LNG plant in Indonesia, covering spare parts, repair services, and technical support for critical turbomachinery across three LNG trains.

Baker Hughes
8/26/2025, 11:00:00 AM

Latest News

Baker Hughes Awarded Long-Term Service Agreement by bp for Tangguh LNG Operations, Supporting Indonesia's Energy Future

Baker Hughes Awarded Long-Term Service Agreement by bp for Tangguh LNG Operations, Supporting Indonesia's Energy Future

Baker Hughes secured a 90-month service agreement with bp for the Tangguh LNG plant in Indonesia, covering spare parts, repair services, and technical support for critical turbomachinery across three LNG trains.

Baker Hughes8/26/2025, 11:00:00 AM
Elon Musk’s Next ‘Monumental Project' Poised to Redefine America’s Future?

Elon Musk’s Next ‘Monumental Project' Poised to Redefine America’s Future?

James Altucher reveals Elon Musk's ambitious AI Mothership project, which could potentially generate $20 trillion in new wealth annually by 2030 and fundamentally transform technological and societal landscapes.

James Altucher8/26/2025, 11:00:00 AM
PEEK Market worth $2.14 billion by 2030 at 7.5%, says MarketsandMarkets™

PEEK Market worth $2.14 billion by 2030 at 7.5%, says MarketsandMarkets™

The PEEK market is expected to grow from $1.50 billion in 2025 to $2.14 billion by 2030, with a 7.5% CAGR. The market is driven by demand for lightweight, high-performance materials across aerospace, automotive, medical, and electronics industries.

Marketsandmarkets8/26/2025, 11:00:00 AM
Regeneron Announces Positive Results from Phase 3 Trial in Generalized Myasthenia Gravis

Regeneron Announces Positive Results from Phase 3 Trial in Generalized Myasthenia Gravis

Regeneron reported successful Phase 3 trial results for cemdisiran, an investigational treatment for generalized myasthenia gravis, showing significant improvement in patient daily functioning with a quarterly subcutaneous administration. The drug demonstrated a 2.3-point placebo-adjusted improvement in patient-reported outcomes.

Regeneron Pharmaceuticals8/26/2025, 11:00:00 AM
Balchem Corporation to Present at the H.C. Wainwright 27th Annual Global Investment Conference on September 9, 2025

Balchem Corporation to Present at the H.C. Wainwright 27th Annual Global Investment Conference on September 9, 2025

Balchem Corporation will present at the H.C. Wainwright 27th Annual Global Investment Conference on September 9, 2025, with key executives including Ted Harris, Martin Bengtsson, and Allison Baurichter.

Balchem Corporation8/26/2025, 11:00:00 AM
Evoke Pharma and EVERSANA Expand GIMOTI® Access to Gastro Health and Other Large GI Practices through Omnicell Relationship

Evoke Pharma and EVERSANA Expand GIMOTI® Access to Gastro Health and Other Large GI Practices through Omnicell Relationship

Evoke Pharma partnered with EVERSANA and Omnicell to expand access to GIMOTI nasal spray for gastroparesis treatment, targeting large gastroenterology practices and specialty pharmacies through strategic pharmacy network agreements.

Daniel Kontoh-Boateng8/26/2025, 11:00:00 AM
EyePoint Announces Participation at Upcoming Investor Conferences

EyePoint Announces Participation at Upcoming Investor Conferences

EyePoint Pharmaceuticals will participate in multiple healthcare investment conferences in September 2025, presenting its lead product DURAVYU, an investigational sustained delivery treatment for retinal diseases.

Eyepoint Pharmaceuticals, Inc.8/26/2025, 11:00:00 AM
Marker Therapeutics Provides Update on Phase 1 APOLLO Study Highlighting Encouraging Overall Response Rates in Relapsed Lymphoma

Marker Therapeutics Provides Update on Phase 1 APOLLO Study Highlighting Encouraging Overall Response Rates in Relapsed Lymphoma

Marker Therapeutics reported promising results from its Phase 1 APOLLO study of MT-601, a multi-antigen T cell therapy for lymphoma. The study showed 66% objective response rates in Non-Hodgkin Lymphoma patients, with 50% achieving complete response and a favorable safety profile.

Marker Therapeutics8/26/2025, 11:00:00 AM
Telix to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference and H.C. Wainwright 27th Annual Global Investment Conference

Telix to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference and H.C. Wainwright 27th Annual Global Investment Conference

Telix Pharmaceuticals will present at two investment conferences in September 2025, with CEO Dr. Christian Behrenbruch participating in fireside chats in New York, discussing the company's biopharmaceutical developments.

Telix Pharmaceuticals Limited8/26/2025, 11:00:00 AM
Tango Therapeutics to Participate in the 2025 Cantor Global Healthcare Conference

Tango Therapeutics to Participate in the 2025 Cantor Global Healthcare Conference

Tango Therapeutics' CEO Barbara Weber will participate in a fireside chat at the 2025 Cantor Global Healthcare Conference, presenting a live webcast about the company's precision medicine cancer research.

Barbara Weber, M.D.8/26/2025, 11:00:00 AM